A molecular and epidemiological study on methicillin-resistant *Staphylococcus aureus*

Thesis Submitted for the award of the degree of doctor philosophy in microbiology

By

Eman Samir Hassan Ibrahim

(M.Sc. Microbiology, 2011)

Supervisors

Prof. Mohamed Khaled Ibrahim

Professor of Bacteriology
Department of Microbiology
Faculty Science
Ain Shams University

Prof. Said Mohamed Abd El-All

Professor of Microbiology
National Organization for Drug Control and Research

Prof. Khaled Zakaria El-Baghdady

Professor of Bacteriology
Department of Microbiology
Faculty Science
Ain Shams University

Prof. Mohamed Ali A. Warda

Professor of Biochemistry
Director of Biotechnology unit
Faculty of Veterinary Medicine
Cairo University

Dr. Abdelbary Mohamed Prince

Associate Professor of Biochemistry
Faculty of Veterinary Medicine
Cairo University

Microbiology Department,
Faculty of Science,
Ain Shams University

2020

Dedication

I would like to take this opportunity to express my profound gratitude to my mother, my father, my husband and all my family for their love and continuous support throughout my life.

Finally, my thanks go to my friends and all the people who have supported me to complete the research work directly or indirectly.

Declaration

This thesis has not previously been submitted to any other university. The references were being checked whenever possible; show the extent to which I have availed myself of the work of other authors.

Eman Samir Hassan Ibrahim

Acknowledgment

First of all, everlasting thanks to “ALLAH “to whom I relate any success in life.

First of all praises and thanks to ALLAH, for brightening my way to complete this work, and guiding me during my study to many bright and helpful people who supported me along the way.

I am grateful and thankful to Prof. Dr. Mohamed Khaled Ibrahim, Professor of Bacteriology, Department of Microbiology, Faculty Science-Ain Shams University for his continuous support in all my thesis steps and help me with his experience that enabled and helped me to achieve this work.

I would like to express my sincere gratitude to Prof. Dr. Khaled Zakaria El-Baghdady, Professor of Bacteriology, Department of Microbiology, Faculty Science-Ain Shams University for his valuable recommendations and being friendly and helpful in my study.

I would like to thank Prof. Dr Said Mohamed Abd El-All for his great efforts in all practical part which assisted in completing this work.

Also all thanks and respect to Prof. Dr. Sahar M. Tolba, Professor of Bacteriology, Department of Microbiology, Faculty Science-Ain Shams University for supporting and helping me.

Many thanks are extended to all the staff members of the department of microbiology, NODCAR for their help and support through my work.

Finally, special thanks goes deep gratitude and respect to all members of Microbiology Department, Faculty of Science, Ain Shams University for support.

CONTENTS

Title	Page No.
List of Tables	V
List of Figures	VII
List of Abbreviations	X
Abstract	XIV
Introduction	1
Aim of work	3
1.Literature Review	4
1.1 History of Staphylococci	4
1.2 Classification of *Staphylococcus aureus*	8
1.3 Morphology and characteristics of *Staphylococcus aureus*	9
1.4 Cultural characteristics of *Staphylococcus aureus*	9
1.5 Identification of *Staphylococcus aureus*	11
1.6 Diagnosis identification of MRSA from clinical specimens	12
1.7 Environmental distribution of *Staphylococcus aureus*	13
1.8 Epidemiology of *S. aureus* infections	14
1.9 Diseases caused by *S. aureus*	16
1.9.1 Bacteraemia	16
1.9.2 Endocarditis	17

1.9.3 Toxic shock syndrome	18
1.9.4 Food poisoning	19
1.9.5 Staphylococcal scalded skin syndrome	21
1.9.6 Pathogenesis and virulence of *S. aureus* infections	22
1.10 Antibiotic resistance of *S. aureus* strains	27
1.10.1 Penicillin resistance	28
1.10.2 Methicillin resistance in *S. aureus* strains	39
1.10.2.1 Community-associated MRSA strains	30
1.10.3 Vancomycin-resistance in *S .aureus* strains	33
1.10.4 Fluoroquinolone resistance in *S. aureus* strains	37
1.11 Treatment and prevention of *S. aureus* infections	38
2. Materials and Methods	40
2.1 Materials	40
2.1.1 Collection of clinical isolates	40
2.1.2 Culture media	40
2.1.3Reagents, buffers and solutions	47
2.2. Methods	50
2.2.1Collection of clinical isolates	50
2.2.2 Maintenance of clinical isolates	50
2.2.3 Culturing method	50
2.2.4 Identification of *Staphylococcus aureus*	51
2.2.4.1 Gram stain	51
2.2.4.2 Biochemical identification of *Staphylococcus* spp.	51

2.2.4.2.1 Catalase test	51
2.2.4.2.2 Coagulase test	52
2.2.4.3 Growth on selective medium	53
2.2.5 Identification of methicillin-resistant *Staphylococcus aureus* (MRSA)	54
2.2.5.1 Screening of *Staphylococcus aureus* isolates on oxacillin resistance screening agar base (ORSAB)	54
2.2.5.2 Screening for MRSA isolates using cefoxitin (30 µg) and oxacillin (1 µg) antibiotic discs	55
2.2.6 Antibiotics susceptibility test of MRSA isolates by disk diffusion method	56
2.2.7 Determination of minimum inhibitory concentration (MIC) of oxacillin using agar diffusion method	59
2.2.8 Genotypic detection of *Type I, Type II, Type III, Type Iva, Type IVb, Type IVc, Type IVd, Type V, MecA* and *Luk-PV* genes in selected MRSA isolates by polymerase chain reaction (PCR)	59
2.2.8.1 DNA extraction	59
2.2.8.2 Polymerase chain reaction (PCR) for detection of genes in selected MRSA isolates	60
2.2.8.3 Amplification reaction set-up	60
2.2.8.4 PCR programs for different genes amplifications	62
2.2.8.5 DNA electrophoresis	63

3. Results	64
3.1 Collection of clinical isolates	64
3.2 Identification of the bacterial isolates	68
3.3 Phenotypic identification of MRSA	75
3.3.1 Screening of *Staphylococcus aureus* isolates on oxacillin resistance screening agar base (ORSAB) medium	75
3.3.2 Screening for MRSA isolates using 30 µg cefoxitin and 1 µg oxacillin disks	75
3.3.3 Distribution of MRSA in different clinical isolates	77
3.4 Antibiotics susceptibility test of MRSA isolates	80
3.5 Determination of minimum inhibitory concentration (MIC) of oxacillin for MRSA isolates	92
3.6 Genotypic analysis of selected MRSA clinical isolates	96
4. Discussion	105
Summary	124
conclusion	127
References	128
الملخص العربى	197

LIST OF TABLES

Table No	Title	Page No
(1)	Summary of toxins and toxic components produced by *S. aureus* (Timbury *et al*., 2002)	25
(2)	Characterisation of the different SCC*mec* types and suggested clinical presentations of MRSA infections **(File, 2008)**	32
(3)	Diameter of inhibition zone (mm) of different groups of antibiotics according to CLSI (2017), with their mode of action.	58
(4)	Primers used for PCR reactions (Makgotlho *et al*., 2009).	61
(5)	Amplification reaction components setup of reaction master mix for each 25 µl reaction	62
(6)	Distribution of collected staphylococcal clinical isolates per genders.	64
(7)	Percentage of staphylococcal clinical isolates according to clinical sources.	65
(8)	Distribution of staphylococcal clinical isolates according to gender in different clinical sources.	67
(9)	Prevalence of *Staphylococcus aureus* among clinical isolates.	69

(10)	Distribution of *S. aureus* isolates in different clinical sources.	73
(11)	Distribution of *S. aureus* isolates in different clinical sources per gender.	74
(12)	Percentage of MRSA among *S. aureus* isolates.	76
(13)	Distribution of MRSA in different clinical sources.	77
(14)	Percentage of MRSA isolates in different clinical sources per gender.	79
(15)	Susceptibility of MRSA isolates to different antibiotics.	81
(16)	Susceptibility pattern of MRSA isolates to different antibiotics.	91
(17)	Minimum inhibitory concentration (MIC) of oxacillin for MRSA isolates.	93
(18)	Percentage of minimum inhibitory concentration of oxacillin for MRSA isolates.	95
(19)	Distribution of different genes in selected MRSA isolates.	97
(20)	Distribution and Percentage of different genes in selected MRSA isolates.	102
(21)	Coexistence of different genes among selected MRSA clinical isolates**.**	104

LIST OF FIGURES

Figure No	Title	Page No
(1)	Global prevalence of MRSA (Grundmann *et al*., 2006)	16
(2)	Schematic representation of the mechanisms of *S. aureus* intermediate resistance to vancomycin The vancomycin-intermediate *S. aureus* strains synthesize additional quantities of peptidoglycan with increased numbers of D-Ala-D-Ala residues that bind vancomycin, thus preventing the molecule to bind to its bacterial target (cell wall) (Lowy, 1998).	35
(3)	Percentage of collected staphylococcal clinical isolates per genders.	64
(4)	Percentage of staphylococcal clinical isolates according to different clinical sources.	66
(5)	Percentage of staphylococcal clinical isolates according to gender in different clinical sources.	68
(6)	Percentages of *Staphylococcus aureus* isolates to other staphylococcal isolates.	70
(7)	Gram stained film prepared from the identified *S. aureus* colonies.	70